Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Bioventus gross margin

Gross margin is gross profit as a percentage of revenue.

Bioventus's gross margin for the twelve months ending Sep 26, 2026 was 68.7%. For fiscal 2025 it was 68.3%, against 67.7% the year before. The highest annual figure on record is 73.3% in fiscal 2019.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	68.3%	+0.6
FY2024	Dec 31, 2024	67.7%	+3.7
FY2023	Dec 31, 2023	64.1%	−0.6
FY2022	Dec 31, 2022	64.6%	−5.6
FY2021	Dec 31, 2021	70.3%	−2.5
FY2020	Dec 31, 2020	72.7%	−0.6
FY2019	Dec 31, 2019	73.3%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 26, 2026	68.2%	+0.2
Q2 FY2026	Jun 27, 2026	69.0%	−0.2
Q1 FY2026	Mar 28, 2026	68.7%	+1.7
Q4 FY2025	Dec 31, 2025	68.9%	+2.1
Q3 FY2025	Sep 27, 2025	68.0%	+0.6
Q2 FY2025	Jun 28, 2025	69.1%	+0.6
Q1 FY2025	Mar 29, 2025	67.0%	−1.2
Q4 FY2024	Dec 31, 2024	66.8%	+3.1
Q3 FY2024	Sep 28, 2024	67.3%	+2.0
Q2 FY2024	Jun 29, 2024	68.5%	+3.5
Q1 FY2024	Mar 30, 2024	68.3%	+6.2
Q4 FY2023	Dec 31, 2023	63.7%	+4.8
Q3 FY2023	Sep 30, 2023	65.3%	−0.4
Q2 FY2023	Jul 1, 2023	65.0%	−3.9
Q1 FY2023	Apr 1, 2023	62.1%	−2.5
Q4 FY2022	Dec 31, 2022	59.0%	−8.3
Q3 FY2022	Oct 1, 2022	65.7%	−6.9
Q2 FY2022	Jul 2, 2022	68.9%	−0.6
Q1 FY2022	Apr 2, 2022	64.5%	−8.3
Q4 FY2021	Dec 31, 2021	67.3%	−7.2
Q3 FY2021	Oct 2, 2021	72.6%	−0.1
Q2 FY2021	Jul 3, 2021	69.5%	−0.1
Q1 FY2021	Apr 3, 2021	72.8%	+0.0
Q4 FY2020	Dec 31, 2020	74.5%	–
Q3 FY2020	Sep 26, 2020	72.7%	–
Q2 FY2020	Jun 27, 2020	69.5%	–
Q1 FY2020	Mar 28, 2020	72.8%	–